The $3 million award recommendation from the U.S. Department of Defense is a significant financial endorsement for Plus Therapeutics, Inc. This funding is expected to support the company's research and development efforts, potentially accelerating the development of its projects and enhancing its financial stability. Such positive news is likely to be viewed favorably by investors, potentially leading to a short-term increase in the company's stock price.